Evidence map›Paper›PMID 39583995›Full record

ReviewAmerican journal of cardiovascular disease2024

Long-term outcomes following ultrathin vs thin-strut drug-eluting stents for percutaneous coronary intervention: an updated systematic review and meta-analysis of randomized control trials.

Farah Yasmin, Syeda Farwa Zaidi, Abdul Moeed, Muneeba Khan, Eman Ali, Muhammad Sohaib Asghar, Waqas Ullah, Michael P Savage, Alec Vishnevsky, Nicholas J Ruggiero and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of cardiovascular disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Farah YasminYale School of Medicine New Haven, CT 06511, USA.
Syeda Farwa ZaidiDow Medical College Karachi 74200, Pakistan.
Abdul MoeedDow Medical College Karachi 74200, Pakistan.
Muneeba KhanJinnah Sindh Medical University Karachi 75510, Pakistan.
Eman AliDow Medical College Karachi 74200, Pakistan.
Muhammad Sohaib AsgharAdvent Health FLorida, USA.
Waqas UllahThomas Jefferson University Hospitals Philadelphia, PA 19107, USA.
Michael P SavageThomas Jefferson University Hospitals Philadelphia, PA 19107, USA.
Alec VishnevskyThomas Jefferson University Hospitals Philadelphia, PA 19107, USA.
Nicholas J RuggieroThomas Jefferson University Hospitals Philadelphia, PA 19107, USA.
David L FischmanThomas Jefferson University Hospitals Philadelphia, PA 19107, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCurrent thin-strut 2

methodsMEDLINE and Scopus were queried from their inception to May 2024 to identify studies comparing outcomes between ultrathin and current thin-strut 2

resultsA total of 17 RCTs (n=22141) with a mean follow-up of 34 months were included. The risk of TLF was significantly lowered in the ultrathin DES group in comparison to thin-strut DES. A significant decrease was also noted in rates of TVF, CD-TLR and CD-TVR in the ultrathin DES vs thin-strut DES group.

conclusionThe results of our analysis demonstrate a significantly reduced risk of TLF in the ultrathin DES group in comparison with thin-strut DES. Ultrathin DES was also associated with a significantly decreased risk of TVF, CD-TLR and CD-TVR.

Indexed as

drug eluting stentsMajor adverse cardiovascular eventstarget lesion revascularization

Identifiers

PMID39583995
PMCPMC11578867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.